A Phase 1b/2, Open-label Study to Investigate the Safety and Efficacy of Invikafusp alfa (STAR0602), a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Combination with Sacituzumab Govitecan in Participants with Unresectable, Locally Advanced, or Metastatic Solid Tumors (START-002)
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3 X CD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome
A phase 2 multicenter study of the combination zanubrutinib, bendamustine, and rituximab in previously untreated Waldenström macroglobulinemia (ZEBRA Trial)
A phase 2 randomized open-label pilot study of Granulocyte Colony Stimulating Factor (G-CSF) to preserve brain structure and function following standard chemoradiation in patients with newly diagnosed MGMT-methylated glioblastoma
A Phase 2 Randomized Study of Adjuvant Immunotherapy With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab Versus Pembrolizumab Alone After Complete Resection of High-Risk Melanoma
A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients with Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib
A phase 2 study of elranatamab as consolidation after idecabtagene vicleucel in relapsed refractory multiple myeloma
A Phase 2 Study of MRD Adapted Therapy with Venetoclax-Obinutuzumab in Patients with High or Intermediate Risk Relapsed or Refractory CLL, with Addition of Acalabrutinib in Patients who Fail to Achieve MRD Eradication
A Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized Breast Cancer (NeoSTAR)
A Phase 2 Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
